|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Ampicillin-Sulbactam]] |
| {{Ampicillin sulbactam}}
| |
| {{CMG}}
| |
| | |
| ==Overview==
| |
| | |
| Ampicillin/sulbactam, the combination of [[ampicillin]] with [[sulbactam]] (an irreversible [[beta-lactamase inhibitor|beta-lactamase inhibitor]]), has an antimicrobial spectrum similar to that of [[amoxicillin]]-[[clavulanic acid|clavulanate]] that includes [[methicillin]]-sensitive strains of [[Staphylococcus aureus]], [[Enterobacteriaceae]] (but not resistant strains of [[Escherichia coli]] or [[Pseudomonas aeruginosa]]), and [[anaerobe]]s. The agent has been used effectively to treat polymicrobial intra-abdominal and pelvic infections. It may also be used for soft tissue infections secondary to human or animal bites.<ref name="Lode-2008">{{Cite journal | last1 = Lode | first1 = HM. | title = Rational antibiotic therapy and the position of ampicillin/sulbactam. | journal = Int J Antimicrob Agents | volume = 32 | issue = 1 | pages = 10-28 | month = Jul | year = 2008 | doi = 10.1016/j.ijantimicag.2008.02.004 | PMID = 18539004 }}</ref>
| |
| | |
| ==Category==
| |
| | |
| Penicillin/β-lactamase inhibitor
| |
| | |
| ==US Brand Names==
| |
| | |
| UNASYN<sup>®</sup>
| |
| | |
| ==FDA Package Insert==
| |
| | |
| ''' [[Ampicillin sulbactam description|Description]]'''
| |
| '''| [[Ampicillin sulbactam clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[Ampicillin sulbactam microbiology|Microbiology]]'''
| |
| '''| [[Ampicillin sulbactam indications and usage|Indications and Usage]]'''
| |
| '''| [[Ampicillin sulbactam contraindications|Contraindications]]'''
| |
| '''| [[Ampicillin sulbactam warnings|Warnings]]'''
| |
| '''| [[Ampicillin sulbactam precautions|Precautions]]'''
| |
| '''| [[Ampicillin sulbactam adverse reactions|Adverse Reactions]]'''
| |
| '''| [[Ampicillin sulbactam overdosage|Overdosage]]'''
| |
| '''| [[Ampicillin sulbactam clinical studies|Clinical Studies]]'''
| |
| '''| [[Ampicillin sulbactam dosage and administration|Dosage and Administration]]'''
| |
| '''| [[Ampicillin sulbactam compatibility reconstitution and stability|Compatibility, Reconstitution, and Stability]]'''
| |
| '''| [[Ampicillin sulbactam directions for use|Directions For Use]]'''
| |
| '''| [[Ampicillin sulbactam how supplied|How Supplied]]'''
| |
| '''| [[Ampicillin sulbactam other size packages available|Other Size Packages Available]]'''
| |
| '''| [[Ampicillin sulbactam labels and packages|Labels and Packages]]'''
| |
| | |
| ==Mechanism of Action==
| |
| | |
| Ampicillin inhibits bacterial [[cell wall]] synthesis by binding to [[penicillin-binding protein]]s which in turn inhibits the transpeptidation (cross-linking) of [[peptidoglycan]]. Thus, cell wall assembly is interrupted and bacteria are lyzed by [[autolysins]] and murein [[hydrolase]]s. Sulbactam irreversibly inhibit [[plasmid]]-mediated [[beta-lactamases]]which are frequently accountable for [[drug resistance]]. In addition, sulbactam has modest activity ''in vitro'' against strains of [[Acinetobacter baumannii]].<ref name="Higgins-2004">{{Cite journal | last1 = Higgins | first1 = PG. | last2 = Wisplinghoff | first2 = H. | last3 = Stefanik | first3 = D. | last4 = Seifert | first4 = H. | title = In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. | journal = Antimicrob Agents Chemother | volume = 48 | issue = 5 | pages = 1586-92 | month = May | year = 2004 | doi = | PMID = 15105109}}</ref> The presence of sulbactam in the formulation extends the spectrum of ampicillin to include beta-lactamase producing strains.
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| [[Category:Antibiotics]]
| |
| [[Category:Wikinfect]]
| |